Abstract
Bioluminescence imaging (BLI) is a facile method for studying androgen receptor (AR) signaling during tumor progression in xenografts and genetic models of prostate cancer in mice. This chapter summarizes work where BLI and positron emission tomography coupled with CT were used to analyze AR-mediated transcriptional activity using gene expression-based imaging approaches.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Adams, J. Y., Johnson, M., Sato, M., Berger, F., Gambhir, S. S., Carey, M., Iruela-Arispe, M. L., and Wu, L.2002. Visualization of advanced human prostate cancer lesions in living mice by a targeted gene transfer vector and optical imaging. Nat Med8: 891–897.
Bok, R. A., and Small, E. J.2002. Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer2: 918–926.
Burton, J. B., Johnson, M., Sato, M., Koh, S. B. S., Mulholland, D., Stout, D., Chatziioannou, A. F., Phelps, M. E., Wu, H., and Wu, L.2008. Adenovirus mediated gene expression imaging to detect sentinel lymph node metastasis of prostate cancer. Nat Med14: 882–888.
Cleutjens, K. B., van der Korput, H. A., van Eekelen, C. C., van Rooij, H. C., Faber, P. W., and Trapman, J.1997. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol11: 148–161.
Cleutjens, K. B., van Eekelen, C. C., van der Korput, H. A., Brinkman, A. O., and Trapman, J.1996. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem271: 6379–6388.
Contag, C. H., and Bachmann, M. H.2002. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng4: 235–260.
Contag, C. H., Jenkins, D., Contag, P. R., and Negrin, R. S.2000. Use of reporter genes for optical measurements of neoplastic disease in vivo. Neoplasia2: 41–52.
Cruzalegui, F. H., Cano, E., and Treisman, R.1999. ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene18: 7948–7957.
Dehdashti, F., Picus, J., Michalski, J. M., Dence, C. S., Siegel, B. A., Katzenellenbogen, J. A., and Welch, M. J.2005. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging32: 344–350.
Dehm, S. M., and Tindall, D. J.2007. Androgen receptor structural and functional elements: role and regulation in prostate cancer. Mol Endocrinol21: 2855–2863.
Ellwood-Yen, K., Wongvipat, J., and Sawyers, C.2006. Transgenic mouse model for rapid pharmacodynamic evaluation of antiandrogens. Cancer Res66: 10513–10516.
Emami, K. H., and Carey, M.1992. A synergistic increase in potency of a multimerized VP16 transcriptional activation domain. Embo J11: 5005–5012.
Gambhir, S. S.2002. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer2: 683–693.
Gingrich, J. R., Barrios, R. J., Morton, R. A., Boyce, B. F., DeMayo, F. J., Finegold, M. J., Angelopoulou, R., Rosen, J. M., and Greenberg, N. M.1996. Metastatic prostate cancer in a transgenic mouse. Cancer Res56: 4096–4102.
Gioeli, D., Mandell, J. W., Petroni, G. R., Frierson, H. F., Jr., and Weber, M. J.1999. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res59: 279–284.
Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., and Wilson, E. M.2001a. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res61: 4315–4319.
Gregory, C. W., Johnson, R. T., Jr., Mohler, J. L., French, F. S., and Wilson, E. M.2001b. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res61: 2892–2898.
Helms, M. W., Brandt, B. H., and Contag, C. H.2006. Options for visualizing metastatic disease in the living body. Contrib Microbiol13: 209–231.
Hexdall, L., and Zheng, C. F.2001. Stable luciferase reporter cell lines for signal transduction pathway readout using GAL4 fusion transactivators. Biotechniques30: 1134–1138, 1140.
Hsieh, C. L., Xie, Z., Liu, Z. Y., Green, J. E., Martin, W. D., Datta, M. W., Yeung, F., Pan, D., and Chung, L. W.2005. A luciferase transgenic mouse model: visualization of prostate development and its androgen responsiveness in live animals. J Mol Endocrinol35: 293–304.
Hsieh, C. L., Xie, Z., Yu, J., Martin, W. D., Datta, M. W., Wu, G. J., and Chung, L. W.2007. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model. Prostate67: 685–691.
Huang, W., Shostak, Y., Tarr, P., Sawyers, C., and Carey, M.1999. Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem274: 25756–25768.
Ignowski, J. M., and Schaffer, D. V.2004. Kinetic analysis and modeling of firefly luciferase as a quantitative reporter gene in live mammalian cells. Biotechnol Bioeng86: 827–834.
Ilagan, R., Pottratz, J., Le, K., Zhang, L., Wong, S. G., Ayala, R., Iyer, M., Wu, L., Gambhir, S. S., and Carey, M.2006. Imaging mitogen-activated protein kinase function in xenograft models of prostate cancer. Cancer Res66: 10778–10785.
Ilagan, R., Zhang, L. J., Pottratz, J., Le, K., Salas, S., Iyer, M., Wu, L., Gambhir, S. S., and Carey, M.2005. Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model. Mol Cancer Ther4: 1662–1669.
Iyer, M., Salazar, F. B., Lewis, X., Zhang, L., Carey, M., Wu, L., and Gambhir, S. S.2004. Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. Mol Ther10: 545–552.
Iyer, M., Salazar, F. B., Lewis, X., Zhang, L., Wu, L., Carey, M., and Gambhir, S. S.2005a. Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy. Transgenic Res14: 47–55.
Iyer, M., Salazar, F. B., Wu, L., Carey, M., and Gambhir, S. S.2006. Bioluminescence imaging of systemic tumor targeting using a prostate-specific lentiviral vector. Hum Gene Ther17: 125–132.
Iyer, M., Sato, M., Johnson, M., Gambhir, S. S., and Wu, L.2005b. Applications of molecular imaging in cancer gene therapy. Curr Gene Ther5: 607–618.
Iyer, M., Wu, L., Carey, M., Wang, Y., Smallwood, A., and Gambhir, S. S.2001. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci U S A98: 14595–14600.
Jacobson, O., Bechor, Y., Icar, A., Novak, N., Birman, A., Marom, H., Fadeeva, L., Golan, E., Leibovitch, I., Gutman, M., et al.2005. Prostate cancer PET bioprobes: synthesis of [18F]-radiolabeled hydroxyflutamide derivatives. Bioorg Med Chem13: 6195–6205.
Johnson, M., Sato, M., Burton, J., Gambhir, S. S., Carey, M., and Wu, L.2005. Micro-PET/CT monitoring of herpes thymidine kinase suicide gene therapy in a prostate cancer xenograft: the advantage of a cell-specific transcriptional targeting approach. Mol Imaging4: 463–472.
Klein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrun, A., Witte, O. N., and Sawyers, C. L.1997. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med3: 402–408.
Latham, J. P., Searle, P. F., Mautner, V., and James, N. D.2000. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res60: 334–341.
Marais, R., Wynne, J., and Treisman, R.1993. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell73: 381–393.
Marcelli, M., Stenoien, D. L., Szafran, A. T., Simeoni, S., Agoulnik, I. U., Weigel, N. L., Moran, T., Mikic, I., Price, J. H., and Mancini, M. A.2006. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem98: 770–788.
Massoud, T. F., and Gambhir, S. S.2003. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev17: 545–580.
Mohler, J. L., Gregory, C. W., Ford, O. H., 3rd, Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., and French, F. S.2004. The androgen axis in recurrent prostate cancer. Clin Cancer Res10: 440–448.
Parent, E. E., Carlson, K. E., and Katzenellenbogen, J. A.2007. Synthesis of 7alpha-(fluoromethyl)dihydrotestosterone and 7alpha-(fluoromethyl)nortestosterone, structurally paired androgens designed to probe the role of sex hormone binding globulin in imaging androgen receptors in prostate tumors by positron emission tomography. J Org Chem72: 5546–5554.
Parent, E. E., Dence, C. S., Sharp, T. L., Welch, M. J., and Katzenellenbogen, J. A.2006. Synthesis and biological evaluation of a fluorine-18-labeled nonsteroidal androgen receptor antagonist, N-(3-[18F]fluoro-4-nitronaphthyl)-cis-5-norbornene-endo-2,3-dicarboxylic imide. Nucl Med Biol33: 615–624.
Rauen, K. A., Sudilovsky, D., Le, J. L., Chew, K. L., Hann, B., Weinberg, V., Schmitt, L. D., and McCormick, F.2002. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res62: 3812–3818.
Reid, K. J., Hendy, S. C., Saito, J., Sorensen, P., and Nelson, C. C.2001. Two classes of androgen receptor elements mediate cooperativity through allosteric interactions. J Biol Chem276: 2943–2952.
Riegman, P. H., Vlietstra, R. J., van der Korput, J. A., Brinkmann, A. O., and Trapman, J.1991. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol5: 1921–1930.
Roudier, M. P., True, L. D., Higano, C. S., Vesselle, H., Ellis, W., Lange, P., and Vessella, R. L.2003. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol34: 646–653.
Sadowski, I., Ma, J., Triezenberg, S., and Ptashne, M.1988. GAL4-VP16 is an unusually potent transcriptional activator. Nature335: 563–564.
Sato, M., Figueiredo, M. L., Burton, J. B., Johnson, M., Chen, M., Powell, R., Gambhir, S. S., Carey, M., and L., W. 2008. Configurations of a two-tiered amplified gene expression system vector to improve the specificity of in vivo prostate cancer imaging. Gene Therapy (under revision).
Sato, M., Johnson, M., Zhang, L., Gambhir, S. S., Carey, M., and Wu, L.2005. Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancer. Clin Cancer Res11: 3743–3749.
Sato, M., Johnson, M., Zhang, L., Zhang, B., Le, K., Gambhir, S. S., Carey, M., and Wu, L.2003. Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther8: 726–737.
Schoder, H., and Larson, S. M.2004. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med34: 274–292.
Schuur, E. R., Henderson, G. A., Kmetec, L. A., Miller, J. D., Lamparski, H. G., and Henderson, D. R.1996. Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem271: 7043–7051.
Seethammagari, M. R., Xie, X., Greenberg, N. M., and Spencer, D. M.2006. EZC-prostate models offer high sensitivity and specificity for noninvasive imaging of prostate cancer progression and androgen receptor action. Cancer Res66: 6199–6209.
Shah, R. B., Mehra, R., Chinnaiyan, A. M., Shen, R., Ghosh, D., Zhou, M., Macvicar, G. R., Varambally, S., Harwood, J., Bismar, T. A., et al.2004. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res64: 9209–9216.
Taplin, M. E.2007. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Nat Clin Pract Oncol4: 236–244.
Weber, M. J., and Gioeli, D.2004. Ras signaling in prostate cancer progression. J Cell Biochem91: 13–25.
Wu, L., Johnson, M., and Sato, M.2003. Transcriptionally targeted gene therapy to detect and treat cancer. Trends Mol Med9: 421–429.
Wu, L., Matherly, J., Smallwood, A., Adams, J. Y., Billick, E., Belldegrun, A., and Carey, M.2001. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors. Gene Ther8: 1416–1426.
Xie, X., Zhao, X., Liu, Y., Young, C. Y., Tindall, D. J., Slawin, K. M., and Spencer, D. M.2001. Robust prostate-specific expression for targeted gene therapy based on the human kallikrein 2 promoter. Hum Gene Ther12: 549–561.
Ye, X., Han, S. J., Tsai, S. Y., DeMayo, F. J., Xu, J., Tsai, M. J., and O'Malley, B. W.2005. Roles of steroid receptor coactivator (SRC)-1 and transcriptional intermediary factor (TIF) 2 in androgen receptor activity in mice. Proc Natl Acad Sci U S A102: 9487–9492.
Zhang, J., Gao, N., Kasper, S., Reid, K., Nelson, C., and Matusik, R. J.2004. An androgen-dependent upstream enhancer is essential for high levels of probasin gene expression. Endocrinology145: 134–148.
Zhang, J., Thomas, T. Z., Kasper, S., and Matusik, R. J.2000. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology141: 4698–4710.
Zhang, L., Adams, J. Y., Billick, E., Ilagan, R., Iyer, M., Le, K., Smallwood, A., Gambhir, S. S., Carey, M., and Wu, L.2002. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther5: 223–232.
Zhang, L., Johnson, M., Le, K. H., Sato, M., Ilagan, R., Iyer, M., Gambhir, S. S., Wu, L., and Carey, M.2003. Interrogating androgen receptor function in recurrent prostate cancer. Cancer Res63: 4552–4560.
Author information
Authors and Affiliations
Corresponding author
Editor information
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Carey, M., Wu, L. (2009). Imaging Androgen Receptor Function In Vivo. In: Mohler, J., Tindall, D. (eds) Androgen Action in Prostate Cancer. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69179-4_4
Download citation
DOI: https://doi.org/10.1007/978-0-387-69179-4_4
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-69177-0
Online ISBN: 978-0-387-69179-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)